Skip to main content
Premium Trial:

Request an Annual Quote

German Dx Firm Taps N-of-One to Provide Clinical Interpretation for NGS Testing

Premium

NEW YORK (GenomeWeb) – N-of-One said this week that it has been selected by CeGaT to interpret data from its next-generation sequencing-based oncology tests.

Under the terms of the agreement, N-of-One will analyze data from CeGaT's NGS panel which tests for more than 550 cancer genes. The company's interpretation results will include biological and clinical information about mutations found in the tumor as well as access to potential therapeutic strategies and clinical trials.

Financial and other terms of the deal were not disclosed

N-of-One's customer base includes Cedars-Sinai Medical Center. The company also has a co-marketing agreement with Appistry that allows both companies sell each other's content, technology, and services.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.